Expression of Estrogen Receptors (α, β), Cyclooxygenase-2 and Aromatase in normal endometrium and endometrioid cancer of uterus

Advances in Medical Sciences

Volumn 58, Issue 1, 2013, Pages 96-103

  Knapp, P ^a   Chabowski, A ^a   Blachnio Zabielska A ^a   Walentowicz Sadlecka M ^b   Grabiec, M ^b   Knapp, P A ^a  

^a MEDICAL UNIVERSITY OF BIALYSTOK   (Poland)

^b NICOLAUS COPERNICUS UNIVERSITY   (Poland)

Author keywords

Aromatase; Cyclooxygenase 2; Endometrial cancer; Estrogen Receptors

Indexed keywords

AROMATASE; CYCLOOXYGENASE 2; ESTROGEN RECEPTOR ALPHA; ESTROGEN RECEPTOR BETA;

ARTICLE; BODY MASS; CANCER RISK; CANCER STAGING; CANCER SURVIVAL; CLINICAL ARTICLE; CONTROLLED STUDY; CORRELATION ANALYSIS; DISEASE FREE SURVIVAL; ENDOMETRIUM CANCER; FEMALE; FOLLOW UP; HUMAN; KAPLAN MEIER METHOD; OBESITY; OVERALL SURVIVAL; PROTEIN EXPRESSION; RISK FACTOR; SURVIVAL RATE; TUMOR GROWTH; WESTERN BLOTTING;

EID: 84886546856     PISSN: 18961126     EISSN: 18984002     Source Type: Journal    
DOI: 10.2478/v10039-012-0055-1     Document Type: Article

References (49)

1. Milne FH, Judge DS, Preen DB, Weinstein P. Early life environment, life history and risk of endometrial cancer. Med Hypotheses. 2011 Oct;77(4):626-32.
2. Ito K, Utsunomiya H, Niikura H, Yaegashi N, Sasano H. Inhibition of estrogen actions in human gynecological malignancies: new aspects of endocrine therapy for endometrial cancer and ovarian cancer. Mol Cell Endocrinol. 2011 Jul 4;340(2):161-7.
3. Nishimura S, Ito YM, Tsuda H, Ohnishi Y, Kataoka F, Nomura H, Chiyoda T, Suzuki A, Susumu N, Aoki D, Hatae M. The sensitivity and specificity of a new formula to distinguish endometrioid type endometrial carcinoma from ovarian endometrial carcinoma. Eur J Obstet Gynecol Reprod Biol. 2010 Jan;148(1):67-72.
4. Ito K. Hormone replacement therapy and cancers: the biological roles of estrogen and progestin in tumorigenesis are different between the endometrium and breast. Tohoku J Exp Med. 2007 May;212(1):1-12. (Pubitemid 46711719)
5. Bokhman JV. Two pathogenetic types of endometrial carcinoma. Gynecol Oncol. 1983 Feb;15(1):10-7. (Pubitemid 13194678)
6. Burbos N, Musonda P, Duncan TJ, Crocker SG, Morris EP, Nieto JJ. Estimating the risk of endometrial cancer in symptomatic postmenopausal women: a novel clinical prediction model based on patients' characteristics. Int J Gynecol Cancer. 2011 Apr;21(3):500-6.
7. Chodick G, Zucker I. Diabetes, gestational diabetes and the risk of cancer in women: epidemiologic evidence and possible biologic mechanisms. Womens Health (Lond Engl). 2011 Mar;7(2):227-37.
8. Heller DS, Mosquera C, Goldsmith LT, Cracchiolo B. Body mass index of patients with endometrial hyperplasia: comparison to patients with proliferative endometrium and abnormal bleeding. J Reprod Med. 2011 Mar-Apr;56(3-4):110-2.
9. Kulie T, Slattengren A, Redmer J, Counts H, Eglash A, Schrager S. Obesity and women's health: an evidence-based review. J Am Board Fam Med. 2011 Jan-Feb;24(1):75-85.
10. Fowler JM, Ramirez N, Cohn DE, Kelbick N, Pavelka J, Ben-Shachar I, Morrison C. Correlation of cyclooxygenase-2 (COX-2) and aromatase expression in human endometrial cancer: tissue microarray analysis. Am J Obstet Gynecol. 2005 Apr;192(4):1262-71.
11. Cohen I. Aromatase inhibitors and the endometrium. Maturitas. 2008 Apr 20;59(4):285-92.
12. Markovitch O, Tepper R, Fishman A, Aviram R, Cohen I. Long-term "protective" effect of aromatase inhibitors on the endometrium of postmenopausal breast cancer patients. Breast Cancer Res Treat. 2009 Jan;113(2):321-6.
13. Mehasseb MK, Panchal R, Taylor AH, Brown L, Bell SC, Habiba M. Estrogen and progesterone receptor isoform distribution through the menstrual cycle in uteri with and without adenomyosis. Fertil Steril. 2011 Jun;95(7):2228-35, 2235.e1.
14. Berstein LM, Poroshina TE, Vasilyev DA, Boyarkina MP. Evaluation of the proportion of hormonal and progenotoxic effects of estrogens and glucose in cancer patients. Bull Exp Biol Med. 2010 Dec;150(2):243-6.
15. Berstein L, Zimarina T, Imyanitov E, Kovalevskij A, Maximov S, Pujol P, Thijssen J. Hormonal imbalance in two types of endometrial cancer and genetic polymorphism of steroidogenic enzymes. Maturitas. 2006 Jul 20;54(4):352-5.
16. Jongen VH, Briet JM, de Jong RA, Joppe E, ten Hoor KA, Boezen HM, Evans DB, Hollema H, van der Zee AG, Nijman HW. Aromatase, cyclooxygenase 2, HER-2/neu, and p53 as prognostic factors in endometrioid endometrial cancer. Int J Gynecol Cancer. 2009 May;19(4):670-6.
17. Rice LW. Hormone prevention strategies for breast, endometrial and ovarian cancers. Gynecol Oncol. 2010 Aug 1;118(2):202-7.
18. Keser SH, Gul AE, Barisik NO, Cakir C, Sensu S, Kandemir NO, Karadayi N. The relationship of COX-2 expression with estrogen receptor, progesterone receptor and prognostic parameters in endometrial carcinomas. J Obstet Gynaecol Res. 2010 Jun;36(3):560-6.
19. Yang S, Thiel KW, De Geest K, Leslie KK. Endometrial cancer: reviving progesterone therapy in the molecular age. Discov Med. 2011 Sep;12(64):205-12.
20. Vandenput I, Trovik J, Leunen K, Wik E, Stefansson I, Akslen L, Moerman P, Vergote I, Salvesen H, Amant F. Evolution in endometrial cancer: evidence from an immunohistochemical study. Int J Gynecol Cancer. 2011 Feb;21(2):316-22.
21. Yemelyanova A, Vang R, Seidman JD, Gravitt PE, Ronnett BM. Endocervical adenocarcinomas with prominent endometrial or endomyometrial involvement simulating primary endometrial carcinomas: utility of HPV DNA detection and immunohistochemical expression of p16 and hormone receptors to confirm the cervical origin of the corpus tumor. Am J Surg Pathol. 2009 Jun;33(6):914-24.
22. O'Mara TA, Fahey P, Ferguson K, Marquart L, Lambrechts D, Despierre E, Vergote I, Amant F, Hall P, Liu J, Czene K, Rebbeck TR, Ahmed S, Dunning AM, Gregory CS, Shah M, Webb PM, Spurdle AB. Progesterone receptor gene variants and risk of endometrial cancer. Carcinogenesis. 2011 Mar;32(3):331-5.
23. Moore NL, Hickey TE, Butler LM, Tilley WD. Multiple nuclear receptor signaling pathways mediate the actions of synthetic progestins in target cells. Mol Cell Endocrinol. 2012 Jun 24;357(1-2):60-70.
24. Yang S, Thiel KW, Leslie KK. Progesterone: the ultimate endometrial tumor suppressor. Trends Endocrinol Metab. 2011 Apr;22(4):145-52.
25. Mountzios G, Pectasides D, Bournakis E, Pectasides E, Bozas G, Dimopoulos MA, Papadimitriou CA. Developments in the systemic treatment of endometrial cancer. Crit Rev Oncol Hematol. 2011 Sep;79(3):278-92.
26. Ulrich LS. Endometrial cancer, types, prognosis, female hormones and antihormones. Climacteric. 2011 Aug;14(4):418-25.
27. Tu BB, Lin SL, Yan LY, Wang ZY, Sun QY, Qiao J. ER-36, a novel variant of estrogen receptor , is involved in EGFR-related carcinogenesis in endometrial cancer. Am J Obstet Gynecol. 2011 Sep;205(3):227.e1-6.
28. Pasqualini JR. Estrogen sulfotransferases in breast and endometrial cancers. Ann N Y Acad Sci. 2009 Feb;1155:88-98.
29. Ota K, Ito K, Suzuki T, Saito S, Tamura M, Hayashi S, Okamura K, Sasano H, Yaegashi N. Peroxisome proliferator-activated receptor gamma and growth inhibition by its ligands in uterine endometrial carcinoma. Clin Cancer Res. 2006 Jul 15;12(14 Pt 1):4200-8.
30. Anderson AS, Caswell S. Obesity management-an opportunity for cancer prevention. Surgeon. 2009 Oct;7(5):282-5.
31. Everett E, Tamimi H, Greer B, Swisher E, Paley P, Mandel L, Goff B. The effect of body mass index on clinical/pathologic features, surgical morbidity, and outcome in patients with endometrial cancer. Gynecol Oncol. 2003 Jul;90(1):150-7. (Pubitemid 37338090)
32. Nasir A, Boulware D, Kaiser HE, Lancaster JM, Coppola D, Smith PV, Hakam A, Siegel SE, Bodey B. Cyclooxygenase-2 (COX-2) expression in human endometrial carcinoma and precursor lesions and its possible use in cancer chemoprevention and therapy. In Vivo. 2007 Jan-Feb;21(1):35-43.
33. Niwa K, Lian Z, Onogi K, Yun W, Tang L, Mori H, Tamaya T. Preventive effects of glycyrrhizin on estrogenrelated endometrial carcinogenesis in mice. Oncol Rep. 2007 Mar;17(3):617-22.
34. Zhou XL, Lei ZM, Rao CV. Treatment of human endometrial gland epithelial cells with chorionic gonadotropin/luteinizing hormone increases the expression of the cyclooxygenase-2 gene. J Clin Endocrinol Metab. 1999 Sep;84(9):3364-77. (Pubitemid 30646969)
35. Orejuela FJ, Ramondetta LM, Smith J, Brown J, Lemos LB, Li Y, Hollier LM. Estrogen and progesterone receptors and cyclooxygenase-2 expression in endometrial cancer, endometrial hyperplasia, and normal endometrium. Gynecol Oncol. 2005 May;97(2):483-8. (Pubitemid 40614893)
36. Tong BJ, Tan J, Tajeda L, Das SK, Chapman JA, DuBois RN, Dey SK. Heightened expression of cyclooxygenase-2 and peroxisome proliferator-activated receptor-delta in human endometrial adenocarcinoma. Neoplasia. 2000 Nov-Dec;2(6):483-90. (Pubitemid 32098682)
37. Fujiwaki R, Iida K, Kanasaki H, Ozaki T, Hata K, Miyazaki K. Cyclooxygenase-2 expression in endometrial cancer: correlation with microvessel count and expression of vascular endothelial growth factor and thymidine phosphorylase. Hum Pathol. 2002 Feb;33(2):213-9. (Pubitemid 34298737)
38. Ishibashi M, Fujiwaki R, Nakayama I, Miura H, Sawada K. Endometrial carcinosarcoma presenting as a tibial metastasis. Int J Clin Oncol. 2007 Aug;12(4):305-8. (Pubitemid 47262731)
39. Ferrandina G, Ranelletti FO, Gallotta V, Martinelli E, Zannoni GF, Gessi M, Scambia G. Expression of cyclooxygenase-2 (COX-2), receptors for estrogen (ER), and progesterone (PR), p53, ki67, and neu protein in endometrial cancer. Gynecol Oncol. 2005 Sep;98(3):383-9. (Pubitemid 41169148)
40. Ferrandina G, Legge F, Ranelletti FO, Zannoni GF, Maggiano N, Evangelisti A, Mancuso S, Scambia G, Lauriola L. Cyclooxygenase-2 expression in endometrial carcinoma: correlation with clinicopathologic parameters and clinical outcome. Cancer. 2002 Aug 15;95(4):801-7. (Pubitemid 34839672)
41. Pathirage N, Di Nezza LA, Salmonsen LA, Jobling T, Simpson ER, Clyne CD. Expression of aromatase, estrogen receptors, and their coactivators in patients with endometrial cancer. Fertil Steril. 2006 Aug;86(2):469-72. (Pubitemid 44118947)
42. Begum MR, Ferdous J, Begum A, Quadir E. Comparison of efficacy of aromatase inhibitor and clomiphene citrate in induction of ovulation in polycystic ovarian syndrome. Fertil Steril. 2009 Sep;92(3):853-7.
43. Bellone S, Shah HR, McKenney JK, Stone PJ, Santin AD. Recurrent endometrial carcinoma regression with the use of the aromatase inhibitor anastrozole. Am J Obstet Gynecol. 2008 Sep;199(3):e7-e10.
44. Bershten LM, Kovalevski AIu, Maksimov SIa, Gershfel'd ED, Meshkova IE, Tsyrlina EV, Poroshina TE, Vasil'ev DA, Thijssen JH. Comparison of letrozole and exemestane used in non-adjuvant therapy of endometrial carcinoma. Vopr Onkol. 2005;51(1):71-4. Russian. (Pubitemid 40445298)
45. Berstein L, Kovalevskij A, Zimarina T, Maximov S, Gershfeld E, Vasilyev D, Baisheva S, Baymakhasheva A, Thijssen JH. Aromatase and comparative response to its inhibitors in two types of endometrial cancer. J Steroid Biochem Mol Biol. 2005 May;95(1-5):71-4. (Pubitemid 41137296)
46. Berstein L, Maximov S, Gershfeld E, Meshkova I, Gamajunova V, Tsyrlina E, Larionov A, Kovalevskij A, Vasilyev D. Neoadjuvant therapy of endometrial cancer with the aromatase inhibitor letrozole: endocrine and clinical effects. Eur J Obstet Gynecol Reprod Biol. 2002 Nov 15;105(2):161-5.
47. Tarkowski R, Skrzypczak M, Winiarczyk S, Kotarski J, Jakowicki JA, Jakimiuk AJ.Aromatase (P450AROM) mRNA expression in normal, hyperplastic and malignant endometrium and aromatase activity in endometrial cancer tissue culture. Ginekol Pol. 2000 Mar;71(3):130-5. Polish.
48. Segawa T, Shozu M, Murakami K, Kasai T, Shinohara K, Nomura K, Ohno S, Inoue M. Aromatase expression in stromal cells of endometrioid endometrial cancer correlates with poor survival. Clin Cancer Res. 2005 Mar 15;11(6):2188-94. (Pubitemid 40490177)
49. Tomao F, Spinelli G, Vici P, Pisanelli GC, Cascialli G, Frati L, Panici PB, Tomao S. Current role and safety profile of aromatase inhibitors in early breast cancer. Expert Rev Anticancer Ther. 2011 Aug;11(8):1253-63.